We are the combination of four hospitals: the General Hospital, the Children’s Hospital, the Women’s Hospital and the Traumatology, Rehabilitation and Burns Hospital. We are part of the Vall d’Hebron Barcelona Hospital Campus: a world-leading health park where healthcare plays a crucial role.
Patients are the centre and the core of our system. We are professionals committed to quality care and our organizational structure breaks down the traditional boundaries between departments and professional groups, with an exclusive model of knowledge areas.
Would you like to know what your stay at Vall d'Hebron will be like? Here you will find all the information.
The commitment of Vall d'Hebron University Hospital to innovation allows us to be at the forefront of medicine, providing first class care adapted to the changing needs of each patient.
Treatment with the drug levodopa allows many of the functions deteriorated or lost due to the disease to be restored. It is the most effective treatment, but it also has limitations: as the disease progresses, its effect becomes transient and fluctuates. When the medication is working, the patient feels well, in the "On" state. When the effect wears off, the patient enters the "Off" state, and symptoms reappear.
To improve the effects of levodopa, different routes of administration have been investigated (inhaled, transdermal, intrajejunal) and various pharmaceutical formulations have been developed. Administration via gastrostomy with a levodopa gel infusion has been particularly successful.
There are also other pharmacological and neurosurgical treatments, such as electrical stimulation of specific brain areas, which provide good results. Research is ongoing to target the diseased brain using stereotactic ultrasound, avoiding trepanation and traditional surgery.
New avenues of research have opened in Parkinson’s disease to determine its causes, prevent its progression, and maximize symptom management.
Low-intensity physical exercise, practiced regularly and consistently—such as simply walking for half an hour to an hour each day—helps preserve automatic and semi-automatic motor functions.
Walking involves two aspects of movement: voluntary and automatic. The voluntary movement would be the act of taking steps, while others—such as arm swinging, foot placement when stepping, head and neck position, etc.—have an important involuntary component.
All body movements benefit from exercise. The motor abilities we all have, which seem easy and permanent, are not necessarily so. Certain movements—like touching the floor with your fingers while keeping your legs straight—can be lost over time if not practiced.
We need constant maintenance, perhaps of low intensity, but sustained over time, to enjoy the full potential of our bodies throughout life.
Hereditary spastic paraplegias (HSPs) are a group of rare, genetic neurological disorders characterised by progressive weakness and stiffness (spasticity) in the legs. This leads to increasing difficulty with walking over time. They are described as ‘hereditary’ because they are caused by alterations in genes that can be passed on within families. They are also known as familial spastic paraplegias or Strümpell-Lorrain syndrome.
HSPs are considered rare diseases, with symptoms that may begin from childhood to adulthood, depending on the genetic type. Neurologically, the primary problem is a progressive degeneration or dysfunction of the nerve pathways that run from the brain to the spinal cord, which are responsible for controlling limb movement and mainly affect the legs.
There are different forms of HSPs, sometimes classified as “pure” and “complex” types. In the pure forms, the symptoms are mainly limited to difficulty walking due to stiffness in the lower limbs. In the complex forms, in addition to paraparesis, other neurological symptoms or involvement of other organs may occur. To date, more than 80 genes have been identified in which mutations can cause HSPs. This explains the variability within HSPs, although each genetic type may present differently in each patient or family.
Although HSPs share the characteristic of leg spasticity with cerebral palsy, they are a distinct condition. In HSPs, there is no fixed brain injury present at birth, but rather a genetic alteration that causes a slow and progressive development of symptoms, which can sometimes be difficult to detect.
The main symptom of HSPs is progressive difficulty walking, caused by a combination of muscle weakness and spasticity in the legs. The most common signs and symptoms are:
HSPs can affect people of any age, although symptoms usually begin in childhood or adolescence. Both men and women can be affected by the condition.
Diagnosis involves several tests, which you can find here, and include:
At Vall d’Hebron University Hospital, patients benefit from the most advanced genetic sequencing techniques to achieve a precise molecular diagnosis quickly and efficiently. However, a proportion of patients still remain undiagnosed. That is why we are engaged in research to try to diagnose all cases and participate in international registries and projects aimed at improving the clinical assessment of patients.
You can view the HSP diagnosis infographic here.
Monitoring of the disease includes:
Currently, there is no cure, but multiple treatments are available to improve symptoms and quality of life:
The hospital offers cutting-edge surgical techniques and access to clinical trial units, enabling patients with HSPs to benefit from experimental therapies and innovative treatments.
HSPs can present at different stages of life and are chronic conditions that require long-term monitoring. At Vall d’Hebron Hospital, lifelong follow-up is ensured from the prenatal period through to adulthood. We also collaborate in research and ensure a smooth and effective transition through joint consultations and efficient communication. We also collaborate with patient associations to support research and raise public awareness about these conditions.
Discover more about the disease in this video:
The Epilepsy Unit provides specialised, high-quality care for both adult and paediatric patients with epilepsy. We are an international centre of excellence and have the largest multidisciplinary team of professionals in Spain offering personalised, comprehensive care for people with epilepsy, including diagnosis, treatment, and ongoing follow-up at our outpatient clinics.
At the Epilepsy Unit we provide expert, specialised care for adults and children with epilepsy. With over 20 years of experience, we are recognised internationally as a reference centre. Our multidisciplinary team offers personalised and comprehensive attention to each patient.
The acceptance of these terms implies that you give your consent to the processing of your personal data for the provision of the services you request through this portal and, if applicable, to carry out the necessary procedures with the administrations or public entities involved in the processing. You may exercise the mentioned rights by writing to web@vallhebron.cat, clearly indicating in the subject line “Exercise of LOPD rights”. Responsible entity: Vall d’Hebron University Hospital (Catalan Institute of Health). Purpose: Subscription to the Vall d’Hebron Barcelona Hospital Campus newsletter, where you will receive news, activities, and relevant information. Legal basis: Consent of the data subject. Data sharing: If applicable, with VHIR. No other data transfers are foreseen. No international transfer of personal data is foreseen. Rights: Access, rectification, deletion, and data portability, as well as restriction and objection to its processing. The user may revoke their consent at any time. Source: The data subject. Additional information: Additional information can be found at https://hospital.vallhebron.com/es/politica-de-proteccion-de-datos.